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Abstract: Lung cancer, breast cancer and colorectal cancer are the most prevalent fatal types of
cancers globally. Gallic acid (3,4,5-trihydroxybenzoic acid) is a bioactive compound found in
plants and foods, such as white tea, witch hazel and it has been reported to possess anticancer,
antioxidant and anti-inflammatory properties. In this study we have redesigned our previously
reported anticancer nanocomposite formulation with improved drug loading based on iron oxide
magnetite nanoparticles coated with polyethylene glycol and loaded with anticancer drug gallic
acid (Fe3O4-PEG-GA). The in vitro release profile and percentage drug loading were found to be
better than our previously reported formulation. The anticancer activity of pure gallic acid (GA),
empty carrier (Fe3O4-PEG) nanocarrier and of anticancer nanocomposite (Fe3O4-PEG-GA) were
screened against human lung cancer cells (A549), human breast cancer cells (MCF-7), human colon
cancer cells (HT-29) and normal fibroblast cells (3T3) after incubation of 24, 48 and 72 h using
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT assay. The designed formulation
(Fe3O4-PEG-GA) showed better anticancer activity than free gallic acid (GA). The results of the in vitro
studies are highly encouraging to conduct the in vivo studies.
Keywords: gallic acid; magnetite nanoparticles; anticancer; PEG; lung cancer; colon cancer
1. Introduction
Cancer is one of the serious concerns around the world and it is one of the main causes of
death worldwide [1]. In a press release by the World Health Organization in 2014, it was reported
that cancer accounted for 8.2 million deaths worldwide in 2012 with lung, breast and colorectal
cancers identified as most common occurrences worldwide in the year 2012 [2]. This was further
supported by a press release by the World Health Organization in 2015. According to the Cancer
statistics 2017, in the United States alone, about 1,688,780 new cancer cases and 600,920 cancer
deaths are projected to occur [3]. Current cancer treatments rely on radiation and chemotherapeutic
agents that work by killing rapidly dividing cells in the body. The main drawback of conventional
chemotherapy is the adverse effects on the body as it cannot deliver selective action specifically to
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the cancer cells, thus damaging the surrounding normal healthy cells or rapidly dividing healthy
cells such as the cells of gastrointestinal tract, bone marrow, hair follicles, causing issues like cardiac,
hepatic, pulmonary, renal and gastrointestinal toxicities [4–6]. Drug delivery systems offer numerous
advantages over tradition chemotherapy such as targeted delivery at disease site, sustained release
leading to prolonged bioavailability, lower dosage requirement and improved drug solubility among
others [7–12]. Significant impact has been made by the application of nanotechnology in medicine
for theranostic agents development which can diagnose and cure the diseases simultaneously [13,14].
Variety of nanocarriers have been designed and successfully applied for the delivery of the therapeutic
agents such as graphene oxide, polymers-based delivery systems, layered double hydroxides, gold
nanoparticles, multifunctional nanoparticles and iron oxide magnetite nanoparticles [8,15–21]. Polymer
coated iron oxide magnetite nanoparticles (Fe3O4) have received much of the attention as the novel
cancer therapeutics vectors because of their unique properties such as ease of preparation, easily
scalable production, sustained release properties, high encapsulation capacity, biocompatibility with
normal cells and tissues, easier surface modification and stable magnetic nature [9,22–26]. All of these
characteristics make iron oxide magnetite nanoparticles (Fe3O4) an ideal candidate for cancer delivery
vectors. However, the large surface area to volume ratio and the dipole-dipole attraction causes
the agglomeration of nanoparticles, hence the need for surface polymer modification. The magnetic
nanocarriers need to be stable in normal saline and water at neutral pH for biological, medical
diagnostic and therapeutic applications [23,27]. To avoid agglomeration, the surface of iron oxide
magnetite nanoparticles is coated with polymer which also helps in sustained release and better
stability in physiological conditions. The polymer poly (ethylene-glycol) (PEG) has been widely
applied in drug delivery and is being utilized as protective layer for the nanoparticles. The monomer
unit of PEG contains both polar oxygen and two methylene group which are non-polar. This dual
polarity makes PEG to be soluble in variety of polar and non-polar solvents and has been widely
used to improve aqueous solubility of hydrophobic drugs [28,29]. Gallic acid (3,4,5-trihydroxybenzoic
acid) is a bioactive compound found in plants and foods such as white tea, witch hazel and it has
been reported to possess antioxidant, anti-inflammatory, anticancer properties and is also known
for its protective activity on normal cells which makes them pivotal for cancer therapy [30]. In this
study we have redesigned an anticancer nanocomposite formulation of Gallic acid loaded on iron
oxide magnetite nanoparticles coated with polyethylene glycol (Fe3O4-PEG-GA) with improved drug
loading and better sustained release properties and was characterized by X-ray diffraction (XRD),
dynamic light scattering (DLS), in vitro cytotoxicity assay and drug loading quantification. In previous
study we tested Gallic acid nanocomposite formulation [(P-Fe3O4-PEG-GA) (in formula P stands
for previous)] against MCF-7, a breast cancer cell line with the IC50 value of 11.61 ± 0.12 µg/mL
and human normal lung fibroblast cells MRC-5 was used as a model for normal cell in which more
than 80% cell viability was observed after 72 h incubation [31]. In this study we tested the free drug
GA, empty nanocarrier and the anticancer nanocomposite formulation Fe3O4-PEG-GA against A549
human lung carcinoma cells, HT29 human colon adenocarcinoma cell line, repeated on MCF-7 breast
cancer cells and normal 3T3 cells for incubation period of 24, 48 and 72 h.
2. Results
2.1. Physicochemical Characterization
2.1.1. X-ray Diffraction (XRD) Analysis
Figure 1a shows the XRD patterns of iron oxide magnetite nanoparticles (Fe3O4) alone,
poly ethylene glycol (PEG) and anticancer nanocomposite Fe3O4-PEG-GA. Iron oxide magnetite
nanoparticles (Fe3O4) showed the six characteristics peaks ascribed to Brag reflections due to (220),
(311), (400), (422), (511), and (440) and these peaks can be observed at 2θ = 30.16◦, 35.95◦, 43.34◦,
54.17◦, 57.27◦ and 62.98◦ respectively. The pure polymer PEG showed two main characteristics high
intensity peaks at about 2θ = 19.3◦ and 23.5◦. The pure gallic acid (GA) has been reported to show
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many peaks between the 2θ of 10–50◦ as reported previously [31,32]. In the XRD patterns of the
nanocomposite Fe3O4-PEG-GA characteristic peaks of iron oxide magnetite nanoparticles (Fe3O4),
PEG and of the pure drug peaks are present with slight lesser intensity. The presence of characteristic
peaks of Fe3O4, PEG and GA in the final anticancer nanocomposite confirms the successful formation
of the nanocomposite Fe3O4-PEG-GA.
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Figure 1. (a) X-ray Diffraction (XRD) analysis of iron oxide magnetite nanoparticles (Fe3O4), poly ethylene
glycol (PEG) and anticancer nanocomposite Fe3O4-PEG-GA; (b) Particle size with cumulative and volume
distribution of nanocomposite Fe3O4-PEG-GA; (c) Release of GA from the nanocomposite (Fe3O4-PEG-GA)
of iron oxide magnetite nanoparti les (Fe3O4) coated with polyethylene glycol (PEG) with loaded with
gallic acid (GA) being the active anticancer agent.
2.1.2. Dynamic Ligh Sc tteri g (DLS)
The size of the anticancer nanocomposite Fe3O4-PEG-GA was determined using Zetasizer by
dynamic light scattering (DLS). The sample was dispersed in water and sonicated for 15 min and
then analyzed with Zetasizer. The sample was found to have narrow size distribution between 5 and
12 nm with average particle size of 10 nm as shown in Figure 1b. This size distribution is much smaller
compared to previously reported (P-Fe3O4-PEG-GA) which had wide distribution 20–50 nm with
average size of 31.44 nm [31].
2.1.3. In vitro Release Studies
Release behavior of GA from the nanocomposite Fe3O4-PEG-GA was conducted in human body
simulated buffer saline (PBS) solution of pH 7.4 (human blood pH) and in pH 4.8 (intracellular
lysosomal pH) as shown in Figure 1c. For the release studies 10 mg of the nanocomposite was put in
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10 mL PBS solution of pH 7.4 and pH 4.8 in thermostat at 37 ◦C with constant shaking. At different
time points 3 mL aliquot was taken out and replaced with new buffer of either solution of pH 7.4
and pH 4.8 respectively and analyzed for the percentage release using UV-Vis spectrophotometer
(Waltham, MA, USA). The release of GA was found to be sustained in both physiological pHs (7.4 and
4.8) and took 200 h (about 8 days) for the complete release in both conditions as shown in Figure 1c.
The release profile of GA from the nanocomposite Fe3O4-PEG-GA is much more sustained compared to
previously designed nanocomposite P-Fe3O4-PEG-GA which initially showed burst release with more
than 40% drug released in less than 2 h [31]. Moreover, the release profile of free drug GA has been
reported to be extremely fast which took less than 2 min for the complete release [31]. This suggests
that nanocomposite designed (Fe3O4-PEG-GA) has much better sustain release profile compared to
free drug and the previously designed nanocomposite (P-Fe3O4-PEG-GA).
2.1.4. Drug Loading Percentage Quantification
Percentage loading of the GA in the nanocomposite Fe3O4-PEG-GA was determined with (UV-Vis)
spectrophotomer (Waltham, MA, USA) GA acid was extracted (deloaded) from the nanocomposite
Fe3O4-PEG-GA by putting 10 mg of it in 50 mL of 1 molar phosphate buffer saline (PBS) solution, followed
by sonication for an hour and kept in thermostat with constant shaking at 37 ◦C for 10 days. After that
sample was filtered and filtrate was subjected to quantification of GA. For quantification different
concentrations of GA standards were prepared e.g., 25, 50, 100, 150 and 200 ppm and were analyzed and
correlation coefficient (r2) was found to be 0.9918. After that different filtrate was analyzed three times
and loading was found to be 35%. The percentage loading of GA in this redesigned nanocomposite is
much higher (35%) compared to our previously reported designed nanocomposite of Fe3O4-PEG-GA
in which loading percentage of GA was found to be very lower i.e., 7%. The improved loading can be
ascribed to solvent used to dissolve GA i.e., (80% Methanol:20% water).
2.1.5. Cytotoxicity on 3T3 Fibroblast Cells
All the samples e.g., designed anticancer nanocomposite (Fe3O4-PEG-GA), empty nanocarrier
(Fe3O4-PEG) and free dug GA was tested against 3T3 fibroblast cells for cytotoxicity evaluation using
their gradient concentrations i.e., (0.47, 0.94, 1.88, 3.75, 7.5, 15 and 30 µg/mL) and were incubation for
24, 48 and 72 h as shown in Figure 2a–c respectively. Cell viability studies revealed that free drug GA,
empty carrier and the designed nanocomposite (Fe3O4-PEG-GA) were found to be biocompatible with
3T3 cell as the percentage cell viability was found to be about 80% even after 24, 48 and 72 h incubation
at maximum concentration of 30 µg/mL as shown in Figure 2a–c. The MTT results showed that neither
GA, Fe3O4-PEG nor Fe3O4-PEG-GA caused toxicity to 3T3 cells at all time points. As we previously
reported nanocomposite (P-Fe3O4-PEG-GA) was also found to be biocompatible with MRC-5 human
normal lungs cells with percentage cell viability of 100% after 72 h incubation [31]. These results
indicate the high biocompatibility of all the samples.
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Figure 2. (a–c) shows the cell viability (%) of 3T3 cells estimated by MTT assay after 24, 48 and 72 h
incubation respectively; (d–f) shows the cell viability (%) of A549 cells estimated by MTT assay after
24, 48 and 72 h incubation respectively; (g–i) shows the cell viability (%) of MCF-7 cells estimated by
MTT assay after incubation for 24, 48 and 72 h respectively; (j–l) shows the cell viability (%) of HT-29
cells estimated by MTT assay after 24, 48 and 72 h incubation respectively.
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2.1.6. Anticancer Assays
The free drug GA, empty nanocarrier (Fe3O4-PEG) and designed magnetite nanocomposite
formulation (Fe3O4-PEG-GA) were tested against different cancer cell line namely lung cancer cell
(A549), breast cancer cell (MCF-7) and colon cancer cell (HT-29) lines to determine their anticancer
properties. In our previous studies we had tested the nanocomposite (P-Fe3O4-PEG-GA) against
breast cancer cell (MCF-7) in this study we repeated the assay on breast cancer cell (MCF-7) as the
percentage drug loading of GA is different than previously reported (P-Fe3O4-PEG-GA). Doxorubicin,
a chemotherapeutic drug, has been studied extensively and its IC50 values towards the same cancer
cell lines have been reported to be 0.33 ± 0.03, 0.05 ± 0.01 and 0.58 ± 0.01 µg/mL for HT-29, MCF-7
and A549 respectively [33].These IC50 values of Doxorubicin were used as a reference for the positive
control in this study.
2.1.7. Anticancer Activity against Lung Cancer Cell (A549)
Figure 2d–f shows the percentage cell viability of A549 lung cancer cells treated with higher
concentrations i.e., 6.25, 12.5, 25, 50, 100 and 200 µg/mL of the free drug GA, empty nanocarrier
Fe3O4-PEG and the nanocomposite Fe3O4-PEG-GA. Previous anticancer studies involving A549
used a higher range of concentration of GA as well, ranging from a minimum of 10 µg/mL up
to 500 µg/mL [34–36]. All the samples with above concentrations were incubated for 24, 48 and
72 h with the A549 lung cancer cells as shown in Figure 2d–f respectively. The designed anticancer
nanocomposite Fe3O4-PEG-GA showed better anticancer activity (IC50 37.49 µg/mL) compared to free
drug GA (IC50 56.49 µg/mL). The effective IC50 concentration (i.e., actual amount of GA based on
percentage drug loading) present in the nanocomposite 13.12 µg/mL is much lower than IC50 of whole
nanocomposite 37.4 µg/mL. So in reality, effective IC50 of nanocomposite 13.121 µg/mL compared to
IC50 free GA (i.e., 56.49 µg/mL) much lower against lung cancer cells A549. Table 1 shows the IC50 of
free drug GA, and the nanocomposite Fe3O4-PEG-GA compared to Doxorubicin.
Table 1. The IC50 values of GA, Doxorubicin and Fe3O4-PEG-GA on cancer cell lines.
Cancer Cell Lines
IC50 (µg/mL) * Effective IC50 (µg/mL) **
GA Fe3O4-PEG-GA Doxorubicin Fe3O4-PEG-GA
HT29 14.52 ± 0.94 4.85 ± 0.33 0.33 ± 0.03 1.70
MCF-7 21.35 ± 4.14 7.28 ± 0.64 0.05 ± 0.01 2.55
A549 56.49 ± 4.31 37.49 ± 1.42 0.58 ± 0.01 13.1
* Values are expressed as the mean± standard deviation of 3 replicates. The IC50 value is defined as the concentration
of drug needed for 50% cell inhibition; ** Values of actual IC50 that were calculated based on 35% GA loading in
the nanocomposite.
2.1.8. Anticancer Activity against Breast Cancer Cell MCF-7 Cells
All the samples i.e., free drug GA, empty nanocarrier (Fe3O4-PEG) and anticancer nanocomposite
(Fe3O4-PEG-GA) were tested against breast cancer cell MCF-7 cells to screen their anticancer activity.
Different gradient concentrations i.e., 0.47, 0.94, 1.88, 3.75, 7.5, 15 and 30 µg/mL of all the samples were
incubated for 24, 48 and 72 h with breast cancer cell MCF-7 cells and results are shown in Figure 2g–i.
A range of cytotoxicity in a time and dose-dependent manner was observed. The IC50 value of the
nanocomposite Fe3O4-PEG-GA 7.28 µg/mL and its effective IC50 2.548 µg/mL are much lower than
free drug GA IC50 21.35. The IC50 of the this redesigned nanocomposite Fe3O4-PEG-GA nanocomposite
in this in vitro study against breast cancer cell MCF-7 cells is much lower than our previously
reported nanocomposite P-Fe3O4-PEG-GA [31]. The better anticancer activity of nanocomposite
can be attributed to the nanosize and sustained release properties of the anticancer nanocomposite.
Table 1 shows the IC50 vales of the nanocomposite and free drug GA against Doxorubicin.
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2.1.9. Anticancer Activity against Colon Cancer Cell (HT-29)
The free drug GA, empty nanocarrier and the nanocomposite Fe3O4-PEG-GA were tested against
colon cancer cell (HT-29) using different concentrations i.e., 0.47, 0.94, 1.88, 3.75, 7.5, 15 and 30 µg/mL
and incubated for 24, 48 and 72 h as shown in Figure 2j–l respectively. The IC50 of free drug GA was
found to be 15 µg/mL. The IC50 of the nanocomposite Fe3O4-PEG-GA was found 4.85 µg/mL and the
effective IC50 of the nanocomposite Fe3O4-PEG-GA in 4.85 µg/mL was calculated to be 1.697 µg/mL
based on 35% GA loading. The IC50 values are given in Table 1.
3. Discussion
In this study we have redesigned our previously reported an anticancer nanocomposite
formulation of Gallic acid loaded on iron oxide magnetite nanoparticles coated with polyethylene
glycol (Fe3O4-PEG-GA). The XRD patterns of the nanocomposite Fe3O4-PEG-GA showed the
characteristic peaks of iron oxide magnetite nanoparticles (Fe3O4), PEG and of the pure drug peaks
are present with slight lesser intensity. The presence of characteristic peaks of Fe3O4, PEG and
GA in the final anticancer nanocomposite confirms the successful formation of the nanocomposite
Fe3O4-PEG-GA. The average particle size of the anticancer nanocomposite was found to be 10 nm with
a narrow size distribution of 5–12 nm compared to previously reported designed (P-Fe3O4-PEG-GA)
which had wide distribution 20–50 nm with average size of 31.44 nm [31]. The Percentage GA loading
is found to be 35% in this redesigned nanocomposite is much higher compared to our previously
reported nanocomposite of (Fe3O4-PEG-GA) with 7%. In addition to this in vitro release of GA
from the nanocomposite was found to be highly sustained which took about 200 h (about 8 days)
in human body simulated phosphate buffer saline (PBS) solution of pH 7.4 (blood pH) and pH 4.8
(intracellular lysosomal pH) at human body temperature 37 ◦C. In this study we tested the free drug
GA, empty nanocarrier and the anticancer nanocomposite formulation Fe3O4-PEG-GA against A549
human lung carcinoma cells, HT29 human colon adenocarcinoma cell line, repeated on MCF-7 breast
cancer cells and with normal 3T3 cells for incubation period of 24, 48 and 72 h. The IC50 of the designed
nanocomposite Fe3O4-PEG-GA are found to be much lower compared to free drug GA. The effective
IC50 which is based on percentage drug (GA) loading in nanocomposite Fe3O4-PEG-GA which is
even further lower. Table 1 shows the details of the IC50 against A549 human lung carcinoma cells,
HT29 human colon adenocarcinoma cell line, and MCF-7 breast cancer cells and with normal 3T3 cells.
4. Materials and Methods
4.1. Chemicals
Gallic acid of 97% purity, iron oxide coated with polyethylene glycol (PEG) nanocarrier
(Fe3O4-PEG) and gallic acid-iron oxide coated with PEG nanocomposite (Fe3O4-PEG-GA) were
provided by the Material Synthesis and Characterization Laboratory, Institute of Advance Technology
University Putra Malaysia (Serdang Selangor Malaysia). All three drugs were used for the preliminary
screening of the effectiveness between gallic acid nanocomposite and pure gallic acid against
normal cell and three different types of cancer cell lines. To prepare the stock solution, 5 mg
of each drug was initially dissolved in 200 µL of dimethyl sulfoxide (DMSO) before the mixture
was vortexed and sonicated for at least 30 min to ensure that the drug was completely dissolved.
Upon sonication, 800 µL of RPMI 1640 (Nacalai Tesque, Kyoto, Japan) was added and then
vortexed for 2 min to make the total volume of 1 mL. The drug sub stock was further diluted
to a series of concentrations (0.47–200 µg/mL) and was used on the same day it was prepared.
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and Trypsin-EDTA (Ethylene
diamine tetraacetate) (0.25%) were purchased from Nacalai Tesque (Kyoto, Japan).
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4.2. Cell Lines
Normal human fibroblast cells (3T3), human lung cancer epithelial cells (A549), human breast
cancer epithelial cells (MCF-7) and human colon cancer epithelial cells (HT-29) were obtained from
the American Tissue Culture Collection (Manassas, VA, USA). The cells were maintained in Roswell
Park Memorial Institute (RPMI) 1640 medium (Nacalai Tesque, Kyoto, Japan). The growth medium
was supplemented with 10% fetal bovine serum, L-glutamine 15 mmol/L, penicillin 100 U/mL and
streptomycin 100 µg/mL. All cells were incubated at 37 ◦C in humidified 5% CO2/95% air and the
media was replaced every 2 to 3 days.
4.3. In Vitro Cell Viability Assay
The tetrazolium-based Colorimetric Assay (MTT) was used to determine the cytotoxicity of
the drugs on the cancer and normal cell lines. In the case of viable cells in the in vitro MTT assay,
the (nicotinamide adenine dinucleotide phosphate) NADPH-dependent oxidoreductase enzyme that
is produced by the healthy mitochondria of a living cell will be secreted outside the cell membrane
and converts the tetrazolium dye into a purple colored compound called formazan. Cells were first
maintained in drug free media until the cells reached 80–90% confluency. MTT assay was initiated
by the seeding process of plating 1 × 105 cells into each well of a flat bottomed 96-well plate making
the total volume of media in each well 100 µL. The cells were then left to attach for 24 h. Cells were
then treated with increasing concentrations of pure gallic acid (GA), iron oxide-PEG nanocarrier
(Fe3O4-PEG) and gallic acid-iron oxide coated with PEG nanocomposite (Fe3O4-PEG-GA) to make the
final volume of 200 µL per well and incubated in 5% CO2 at 37 ◦C for 24, 48 and 72 h. At the desired
time point, 20 µL of MTT solution (5 mg/mL in PBS) was added to each well and kept in the incubator
for 4 h before the cells were centrifuged to discard the supernatant. 100 µL of DMSO was later added
and left in the dark for 30 min to dissolve the crystal formazan. Absorbance was measured at 570 and
630 nm was used to measure the background absorbance. Experiments were done in triplicates and
cell viability was calculated based on the given formula.
Cell Viability (%) = { (OD∗ of Treated)÷ ( OD∗ of Control)× 100}
OD∗ = Optical density
4.4. Preparation of Magnetite Nanoparticles (Fe3O4), Polyethylene Glycol (PEG) Coating and GA Loading
Iron oxide magnetite nanoparticles (Fe3O4) were prepared by previously reported method,
in brief in 80 mL deionized water containing 6 mL ammonia hydroxide (25%) a mixture of 2.43 g
(FeCl2·4H2O) and 0.99 g (FeCl3·6H2O) was added. After adding the above material sample was subject
to ultrasonication for 1 h. Sample was centrifuged and washed thoroughly with water and dried in
oven at 80 ◦C for 24 h and ground to fine powder [15,26,31]. PEG coating was carried out by dissolving
the 0.2 g of dried iron oxide magnetite nanoparticles (Fe3O4) in 1% of PEG solution followed by stirring
for one hour after that sample was centrifuged and washed with ethanol thoroughly. GA was loaded
on the designed nanocarrier Fe3O4-PEG by putting this sample to 50 mL (40 mL methanol and 10 mL
water) of 1% GA and stirred for 24 h resulting in the formation of Fe3O4-PEG-GA. Next day sample
was washed thoroughly with methanol and water by centrifugation. After that sample was dried in
oven and ground to powder and subjected to further characterization.
5. Conclusions
The designed magnetite nanocomposite Fe3O4-PEG-GA was found to have higher drug GA
loading 35% compared to previously reported nanocomposite with 7% GA loading. The in vitro
release in human physiological pH 7.4 and pH 4.8 at 37 ◦C was conducted and was found to be highly
sustained for up to 8 days compared to previously reported nanocomposite which took 3.5 days
for the complete release and that was conducted at room temperature. In this study the magnetite
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nanocomposite Fe3O4-PEG-GA was found to be biocompatible with normal 3T3 cells. Both GA and
Fe3O4-PEG-GA nanocomposite displayed time and dose-dependent anticancer activity against A549,
MCF-7 and HT-29 cells Most importantly the IC50 of the magnetite nanocomposite Fe3O4-PEG-GA
were found against these cell lines were much better than free drug GA. These in vitro study results
are highly encouraging to go further animal studies.
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